



Regulatory Circular RG02-100

DATE: November 18, 2002

TO: Members and Member Firms

FROM: Market Operations Department

RE: Restrictions on Transactions in
Genzyme Biosurgery (GZBX/TQG)

CBOE intends to add the April 5 option series in Genzyme Biosurgery (GZBX/TQG) for trading beginning on Tuesday, November 19, 2002. However, trading in the TQG April 5 option series is restricted to closing customer orders only.

Only closing transactions may be effected in the TQG April 5 options series, except for (i) opening transactions by market-makers executed to accommodate closing transactions of other market participants and (ii) opening transactions by CBOE member organizations to facilitate the closing transactions of public customers executed as crosses pursuant to and in accordance with CBOE Rule 6.74(b or d). The TQG April 5 options series will not be traded on RAES.

The execution of opening transactions in the TQG April 5 options series, except as permitted above, and/or the misrepresentation as to whether an order is opening or closing, will constitute a violation of CBOE rules, and may result in disciplinary action.

Any questions regarding this circular may directed to Kerry Winters at (312) 786-7312 or Mike Felty at (312) 786-7504.